VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Subjects who voluntarily consented, after          │ Subjects who voluntarily consented, after          │     100 │
│ listening enough explanation for this study and    │ listening enough explanation for this study and    │         │
│ investigational product                            │ investigational product                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Adult over 50 years of age                         │ Adult over 50 years of age                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least one of the knee pain VAS score is 40mm or │ At least one of the knee pain VAS score is 40mm or │     100 │
│ more                                               │ more                                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who require medication for more than 12   │ Patients who require medication for more than 12   │     100 │
│ weeks due to osteoarthritis symptoms               │ weeks due to osteoarthritis symptoms               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Those who are able to follow the requirements of   │ Those who are able to follow the requirements of   │     100 │
│ this clinical trial, such as being able to trace   │ this clinical trial, such as being able to trace   │         │
│ during the clinical trial period and to read and   │ during the clinical trial period and to read and   │         │
│ write the VAS questionnaire                        │ write the VAS questionnaire                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Those who weigh more than 40kg                     │ Those who weigh more than 40kg                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Secondary knee osteoarthritis                      │ Secondary knee osteoarthritis                      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other inflammatory Knee Osteoarthritis (e.g. gout, │ Other inflammatory Knee Osteoarthritis (e.g. gout, │     100 │
│ rheumatoid arthritis, etc.)                        │ rheumatoid arthritis, etc.)                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients presenting with gastroesophageal reflux   │ Patients presenting with gastroesophageal reflux   │     100 │
│ disease, peptic ulcer                              │ disease, peptic ulcer                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Helicobacter infected patients who have not been   │ Helicobacter infected patients who have not been   │     100 │
│ treated for eradication (recruitment if negative   │ treated for eradication (recruitment if negative   │         │
│ in re-examination after treatment)                 │ in re-examination after treatment)                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Short bowel syndrome that can cause inflammatory   │ Short bowel syndrome that can cause inflammatory   │     100 │
│ bowel disease (ulcerative colitis, Crohn's         │ bowel disease (ulcerative colitis, Crohn's         │         │
│ disease) and drug absorption disorder              │ disease) and drug absorption disorder              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intestinal obstruction syndrome                    │ Intestinal obstruction syndrome                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unexplained abdominal pain                         │ Unexplained abdominal pain                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ALT(Alanine aminotransferase) level of liver       │ ALT(Alanine aminotransferase) level of liver       │     100 │
│ function test exceeded 5 times of reference range  │ function test exceeded 5 times of reference range  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Total bilirubin level exceeded 2 mg / dL           │ Total bilirubin level exceeded 2 mg / dL           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum albumin level less than 2 g / dL             │ Serum albumin level less than 2 g / dL             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ascites                                            │ Ascites                                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatic encephalopathy                             │ Hepatic encephalopathy                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B, hepatitis C (excluding healthy        │ Hepatitis B, hepatitis C (excluding healthy        │     100 │
│ carriers) or HIV positive                          │ carriers) or HIV positive                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ MDRD(Modification of Diet in Renal Disease)        │ MDRD(Modification of Diet in Renal Disease)        │     100 │
│ Estimated Glomerular filtration rate less than 60  │ Estimated Glomerular filtration rate less than 60  │         │
│ mL / m2                                            │ mL / m2                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with hyperkalemia (over 5.5 meq / L)      │ Patients with hyperkalemia (over 5.5 meq / L)      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ history of asthma, acute rhinitis, nasal polyps,   │ history of asthma, acute rhinitis, nasal polyps,   │     100 │
│ angioedema, urticaria or allergic reactions to     │ angioedema, urticaria or allergic reactions to     │         │
│ aspirin or other non-steroidal anti-inflammatory   │ aspirin or other non-steroidal anti-inflammatory   │         │
│ drugs(including COX-2 inhibitors)                  │ drugs(including COX-2 inhibitors)                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malignant tumors other than basal cell or squamous │ Malignant tumors other than basal cell or squamous │     100 │
│ cell carcinoma of the skin, CIN(Cervical           │ cell carcinoma of the skin, CIN(Cervical           │         │
│ Intraepitherial Neoplasia) and CIS(Carcinoma in    │ Intraepitherial Neoplasia) and CIS(Carcinoma in    │         │
│ situ) of the cervix, and intraepithelial carcinoma │ situ) of the cervix, and intraepithelial carcinoma │         │
│ of other areas Within 5 years of consent date      │ of other areas Within 5 years of consent date      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical history of hypersensitivity to the         │ Medical history of hypersensitivity to the         │     100 │
│ components of the investigational products. (The   │ components of the investigational products. (The   │         │
│ components of test drug 1 and 2, including the     │ components of test drug 1 and 2, including the     │         │
│ Rhein-based drug)                                  │ Rhein-based drug)                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with an allergic reaction to sulfonamide  │ Patients with an allergic reaction to sulfonamide  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with galactose intolerance, lapp lactase  │ Patients with galactose intolerance, lapp lactase  │     100 │
│ deficiency or glucose-galactose malabsorption      │ deficiency or glucose-galactose malabsorption      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have not reached the prescribed       │ Subjects who have not reached the prescribed       │     100 │
│ period after receiving contraindicated medication  │ period after receiving contraindicated medication  │         │
│ or treatment before participation in this clinical │ or treatment before participation in this clinical │         │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients receiving contraindicated medication      │ Patients receiving contraindicated medication      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alcohol and other drug abuse cases based on 6      │ Alcohol and other drug abuse cases based on 6      │     100 │
│ months before screening                            │ months before screening                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant women or nursing mothers who are not      │ Pregnant women or nursing mothers who are not      │     100 │
│ willing to stop breastfeeding                      │ willing to stop breastfeeding                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (1) Menopause (non-therapy-induced amenorrhea of   │ (1) Menopause (non-therapy-induced amenorrhea of   │     100 │
│ more than 12 months) Female                        │ more than 12 months) Female                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (2) Female infertility due to surgery (no ovaries  │ (2) Female infertility due to surgery (no ovaries  │     100 │
│ and / or uterus)                                   │ and / or uterus)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (3) If you have sexual intercourse with only one   │ (3) If you have sexual intercourse with only one   │     100 │
│ male partner who has been confirmed to have no     │ male partner who has been confirmed to have no     │         │
│ semen after fertilization                          │ semen after fertilization                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (4) Female subjects who agreed to abstinence       │ (4) Female subjects who agreed to abstinence       │     100 │
│ during the clinical trial period                   │ during the clinical trial period                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If the subject is assured of an abstinence         │ If the subject is assured of an abstinence         │     100 │
│ throughout the trial period.(e.g. clergy)          │ throughout the trial period.(e.g. clergy)          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ However, intermittent abstinence (eg,              │ However, intermittent abstinence (eg,              │     100 │
│ contraception using ovulation period,              │ contraception using ovulation period,              │         │
│ symptothermal) or coitus interrupts is not a case  │ symptothermal) or coitus interrupts is not a case  │         │
│ of consent for abstinence                          │ of consent for abstinence                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (5) For women of childbearing age, the following   │ (5) For women of childbearing age, the following   │     100 │
│ methods or methods of contraception use the        │ methods or methods of contraception use the        │         │
│ effective method of contraception to be used       │ effective method of contraception to be used       │         │
│ during the period of this clinical trial           │ during the period of this clinical trial           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Oral contraceptive                                 │ Oral contraceptive                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The contraceptive patch                            │ The contraceptive patch                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intra uterine device (IUD)                         │ Intra uterine device (IUD)                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ contraceptive implant                              │ contraceptive implant                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ contraceptive injection                            │ contraceptive injection                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ intrauterine hormonal apparatus                    │ intrauterine hormonal apparatus                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tubal ligation and infertility surgery             │ Tubal ligation and infertility surgery             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If 30 days have not elapsed after the date of      │ If 30 days have not elapsed after the date of      │     100 │
│ signing of the previous clinical trial or          │ signing of the previous clinical trial or          │         │
│ currently participating in other clinical trials   │ currently participating in other clinical trials   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who are scheduled for surgery during the  │ Patients who are scheduled for surgery during the  │     100 │
│ clinical trial period or who have difficulties in  │ clinical trial period or who have difficulties in  │         │
│ completing the protocol during this clinical trial │ completing the protocol during this clinical trial │         │
│ due to other reasons                               │ due to other reasons                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In addition to the above, other diseases that the  │ In addition to the above, other diseases that the  │     100 │
│ investigator judges to be inappropriate            │ investigator judges to be inappropriate            │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ ② Morning stiffness \<30 minutes                   │ Patients receiving contraindicated medication      │      36 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ③ Crepitus                                         │ Oral contraceptive                                 │      36 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Meets the ACR(American College of Rheumatology)    │ Subjects who have not reached the prescribed       │      43 │
│ criteria for diagnosis. (1) Confirmation of        │ period after receiving contraindicated medication  │         │
│ osteophytes on radiographic inspection. (2) One or │ or treatment before participation in this clinical │         │
│ more of the following three items                  │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 50 Years                  │ Adult over 50 years of age                         │      44 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female who do not fall into one or more of the     │ (3) If you have sexual intercourse with only one   │      46 │
│ following categories(In other words, only the      │ male partner who has been confirmed to have no     │         │
│ following female can participate:)                 │ semen after fertilization                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ① Age\> 50 years                                   │ Adult over 50 years of age                         │      52 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 95
Average Levenshtein Ratio of individual lines: 93.52830188679245
OverAll Ratio: 94.26415094339623
